Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience

Aim Optimal tacrolimus exposure in transplant recipients is not well established. The results from the Symphony study indicated that low‐target tacrolimus (trough concentrations 3–7 µg/L) in de novo standard risk renal transplant recipients should be appropriate. The aim of this study was to evaluate real‐life outcomes when applying a similar strategy in a clinical setting. Methods A single‐centre analysis was conducted in standard risk renal transplant recipients receiving low‐target tacrolimus, mycophenolate mofetil, glucocorticoids and basiliximab induction. One‐year estimated glomerular filtration rate (eGFR, Cockcroft‐Gault), one‐year biopsy‐proven acute rejection rate and graft‐ and patient survival up to 3 years post‐transplant were compared with the outcomes in the Symphony study. Results From 1 January 2009 to 31 March 2013, we included 406 patients. One year after transplantation, the mean ± SD eGFR was 76.8 ± 28.3 mL/min (Symphony: 65.4 ± 27.0 mL/min, P